PharmaVentures appoints senior director
Paul Phull will develop corporate advisory business
PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.
Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.
You may also like
Finance
![Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal]()
Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal
The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for migraine and headache disorders — funded into 2029
Finance
![Prescient completes integration of Uptake and Dolon under single global brand]()
Prescient completes integration of Uptake and Dolon under single global brand
Prescient Healthcare Group has completed the integration of Uptake and Dolon, creating a 550-strong life sciences consultancy spanning commercial strategy, medical affairs, competitive intelligence and market access
Finance
![AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes]()
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes
The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming global rights to ACD856 and the NeuroRestore platform
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
